Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Muscarinic acetylcholine receptors are a family of G protein-coupled receptors responsible for mediating the effects of acetylcholine in the central and peripheral nervous systems. Desipramine, a tricyclic antidepressant, interacts as a minor antagonist at these receptors, contributing to its anticholinergic side effect profile. While desipramine’s primary therapeutic action is inhibition of the norepinephrine transporter, its weak affinity for muscarinic receptors produces modest anticholinergic adverse effects, less severe than other TCAs such as amitriptyline.
Antagonism of muscarinic acetylcholine receptors, leading to anticholinergic effects: reduced parasympathetic activity, cognitive impairment, dry mouth, constipation, urinary retention, blurred vision
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Muscarinic acetylcholine receptor (subtypes: M1, M2, M3, M4, M5) (M1, M2, M3, M4, M5).